Forest Laboratories, Inc. - Value Alert
Texas (July 3, 2013) Wax Ink has issued a Loss of Investment Interest rating for Forest Laboratories, Inc. (NYSE: FRX) based on a recent baseline equity review which placed fair value between $25-$31.
The recent close of $41.71 is approximately 179% above the fair value buy target for the stock and approximately 36% above the fair value close target for the stock. The recent close is also 10% above analysts’ twelve-month $38.00 median price target for the stock.
The recent close represents a 29% increase in price since the last baseline equity review was conducted in November of 2012.
The stock currently has a trailing twelve-month PE Ratio of 129, and a PEG Ratio of (10.3) basis estimated forward earnings growth of (12.5%).
In the past 52 weeks, share prices have moved between a high of $43.85 and a low of $31.28, placing equilibrium at $38.04.
Basis the recent close, the stock is trading 5% below the 52 week high, 25% above the 52 week low, 9% above equilibrium, and has an average daily trading volume of approximately 1.7 million shares.
Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products primarily in the United States and Europe.
The company's competitors include Eli Lilly and Company, GlaxoSmithKline plc, and Pfizer Inc.
Financial information that may be contained herein, is based on the company's most recent annual SEC filing for year ending March 30, 2013. All prices are per share unless otherwise noted.
Wax Ink currently has no investment position in the company mentioned in this alert.
Wax Ink is a baseline equity research company comprised of individual investors, NOT licensed or registered with ANY government agency.
For use by Accredited Investors
as defined under Title 17, CFR §230.500, Regulation D